Home › Funds › ACT Capital Partners, L.P. › NKTR
ACT Capital Partners, L.P. position in NKTR
NEKTAR THERAPEUTICS · Health Care
ACT Capital Partners, L.P. reported holding 90,400 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$5.5M, representing 3.71% of its reported portfolio and ranking #10 among its reported holdings. ACT Capital Partners, L.P. first reported this position in Q3 2026.
Last updated: 2026-11-07 · Source: SEC EDGAR Form 13F-HR
How ACT Capital Partners, L.P.'s NKTR position evolved
ACT Capital Partners, L.P. first disclosed a stake in NKTR in Q3 2026 at 90,400 shares (US$5.5M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 90.40K | $5.47M | New |
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 71 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- Prosight Management, LP 810.00K sh · $56.55M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- 22NW, LP 281.12K sh · $19.62M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- Creek Drive Management Group LLC 243.00K sh · $16.96M · Q2 2026
More on ACT Capital Partners, L.P.
FAQ
How long has ACT Capital Partners, L.P. held NKTR?
ACT Capital Partners, L.P. has disclosed NKTR holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is ACT Capital Partners, L.P.'s current position in NKTR?
As of Q3 2026, ACT Capital Partners, L.P. holds 90.40K shares of NKTR (NEKTAR THERAPEUTICS), valued at $5.47M, representing 3.71% of its reported portfolio and ranking #10.
Has ACT Capital Partners, L.P. been buying or selling NKTR?
In the latest 13F filing (Q3 2026), ACT Capital Partners, L.P. newly opened its position in NKTR.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.